Shire to sell its oncology business to Servier for $2.4 billion

17 Apr 2018

Sale of oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing the company's leadership in rare diseases.

Shire has entered into a definitive agreement with Servier to sell its oncology business for $2.4 billion. Shire’s oncology business includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-US rights to Onivyde (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early-stage immuno-oncology pipeline collaborations.

Shire to sell its oncology business to Servier for $2.4 billion

Flemming Ornskov, Shire CEO, commented: “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the Oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy. We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.

“We are confident that Servier will continue to invest in this business and our colleagues who are expected to transfer as part of the transaction in order to meet the needs of cancer patients globally.

“The proceeds from the transaction increase optionality and Shire’s Board will consider returning the proceeds of the sale to shareholders through a shareholder-approved share buyback after the current offer period regarding Takeda’s possible offer for Shire concludes.”

Olivier Laureau, Servier Group President, commented: “The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present. Our goal is to bring these treatments to greater numbers of cancer patients around the world. We thoroughly look forward to welcoming Shire’s oncology teams who will join Servier after the closing."

Read More

Related tags

Market News

Related news

TraceLink unveils Product Information Manager for its digital information sharing platform

TraceLink unveils Product Information Manager for its digital information sharing platform

12 Jul 2018

Product Information Manager addresses a broad range of use cases, beginning with saleable returns.

Read more 
Stability studies trends

Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Read more 
Recipharm launches standalone serialisation service

Recipharm launches standalone serialisation service

5 Jul 2018

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Read more 
CPhI Worldwide opens entries for 15th Annual Pharma Awards

CPhI Worldwide opens entries for 15th Annual Pharma Awards

5 Jul 2018

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Read more 
Catalent to acquire Juniper Pharmaceuticals

Catalent to acquire Juniper Pharmaceuticals

5 Jul 2018

$133 million deal adds European Early Development Center of Excellence to global network.

Read more 
Insights in lyophilization science

Insights in lyophilization science

4 Jul 2018

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Read more 
Bosch to sell its packaging business

Bosch to sell its packaging business

4 Jul 2018

Packaging technology is not a core Bosch business.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Forté Pharma strengthens its leadership in weight control in France

Forté Pharma strengthens its leadership in weight control in France

1 Jul 2018

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

Read more 
I Holland woos exhibition visitors with new tabletting technologies

I Holland woos exhibition visitors with new tabletting technologies

28 Jun 2018

Company's Wear Indicator Layer attracts the most attention.

Read more